Aernoud Fiolet

211 The efficacy and safety of low-dose colchicine in patients with coronary disease 27 Supplementary Appendix Supplementary Figure S6A: Sensitivity analysis of meta-analysis of colchicine trials using reported end points for the primary and secondary composite end points Composite of myocardial infarction, stroke, or cardiovascular death Composite of myocardial infarction, stroke, coronary revascularisation, or cardiovascular death Pooled relative risks and 95% confidence intervals for the composite of myocardial infarction, stroke, or cardiovascular death (upper panel) and for the composite of myocardial infarction, stroke, coronary revascularisation, or cardiovascular death (lower panel) in patients treated with colchicine as compared to placebo or no colchicine using the end points as reported in the original papers. Abbreviations: CI, confidence interval. GIV, generic inverse variance. Supplementary Figure S6A: Sensitivity analysis of meta-analysis of colchicine trials using reported end points for the primary and secondary composite end points Pooled relative risks and 95% confidence intervals for the composite of myocardial infarction, stroke, or cardiovascul r death (upper panel) and for the composite of myoc rdial infarction, stroke, coronary revascularisation, or cardiovascular death (lower panel) in patients treated with colchicine as compared to placebo or no colchicine usi g the end points as reported in th origi al papers. Abbreviations: CI, confidence interval. GIV, generic inverse variance.